Participants at this year's European Summit of Industrial Biotechnology (ESIB) are going to focus on "design" in biotechnology - at an event that not only covers science but also deals with industrial needs and hopes, economic challenges, funding resources or political aspirations. The ESIB will take place in the historic city of Graz in the heart of Europe from November 14th to 16th, 2016.
Hundreds of scientific conferences and dozens of partnering events and fairs are held per year. Most of them provide great platforms for scientific presentations and exchange of expertise. However, the European Summit of Industrial Biotechnology (ESIB) goes one step further. It has not been designed to be another conference or another partnering event among many others. The ESIB is a platform for industrial biotechnology in multiple contexts. It has been designed to encourage all protagonists of industrial biotechnology to think outside the box and in new and comprehensive dimensions.
This year's vision is about design - this guiding thread of the 2½ days event unites major contributors to international industrial biotechnology under one roof to learn from celebrated experts, executives, and entrepreneurs, to get new inputs from politics and funding agencies and finally to develop profitable ideas with prospective partners.
We invite you to seize the opportunity to discuss vital questions and encouraging topics and to be on top of new insights and trends at the ESIB 2016 from November 14-16 in Graz, Austria. This year's topics will cover trends in biotech science and industry, cascade design and metabolic engineering, designing nature (e.g. proteins for competitive bioprocesses), in-silico approaches in modern industrial biotechnology and much more.
The European Summit of Industrial Biotechnology 2016 is organized by acib, the Austrian Centre of Industrial Biotechnology. Find more information about the ESIB 2016 at http://www.
The Austrian Centre of Industrial Biotechnology (acib) is an international research center for industrial biotechnology with locations in Vienna, Graz, Innsbruck, Linz, Tulln, Hamburg, Heidelberg and Bielefeld (DE), Pavia (IT), Ljubljana (SI), Barcelona (ES) and Rzeszow (PL). Additionally, acib is a scientific and industrial network of 130+ partners, including 3M, G.L. Pharma, Boehringer Ingelheim, DSM, Baxalta, Lon-za, Sandoz, VTU Technology, etc.
At acib, 200+ employees work on more than 70 research projects with the final goal to replace conventional industrial processes and products by more environmentally friendly and more economical approaches. More information about acib's research can be found in acib's "Biotech Stories": goo.gl/3GBEr9
acib is owned by the University of Natural Resources and Life Sciences, Graz University of Technology, the Universities of Innsbruck and Graz and the Styrian Joanneum Research. acib is financed by industrial and public contributions. The latter come from the Austrian Research Promotion Agency of the Republic of Austria (FFG), Standortagentur Tirol, Styrian Business Promotion Agency (SFG), the province of Lower Austria and the Vienna Business Agency.